HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Tegafur

Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.

Also Known As:

1-(2-Tetrahydrofuryl)-5-fluorouracil; 1-(Tetrahydro-2-furanyl)-5-fluorouracil; 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione; Almirall Brand of Tegafur; Bristol-Myers Squibb Brand of Tegafur; FT-207; FT207; Florafur; Fluorofur; Ftorafur; Futraful; N1-(2'-Tetrahydrofuryl)-5-fluorouracil; Prasfarma Brand of Tegafur; Sunfural S; Uftoral; Utefos; Bristol Myers Squibb Brand of Tegafur; FT 207; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-

Networked: 1260 relevant articles (149 outcomes, 378 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sadahiro, Sotaro: 10 articles (12/2015 - 03/2004)
2.	Ichinose, Yukito: 9 articles (11/2013 - 12/2003)
3.	Suzuki, Toshiyuki: 8 articles (06/2014 - 03/2004)
4.	Fukushima, Masakazu: 8 articles (10/2010 - 07/2005)
5.	Ueno, Hideki: 7 articles (01/2012 - 01/2002)
6.	Baba, Hideo: 6 articles (12/2015 - 01/2003)
7.	Ikeda, Masataka: 6 articles (12/2015 - 01/2006)
8.	Lindebjerg, Jan: 6 articles (08/2015 - 10/2006)
9.	Jakobsen, Anders: 6 articles (08/2015 - 10/2006)
10.	Kamijo, Akemi: 6 articles (06/2014 - 03/2004)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 08/01/1987 - "[Comparative clinical studies of colorectal tumor tissue and normal tissue following arterial injection of tegafur]." 05/01/1983 - "Phase II study of ftorafur in previously untreated and treated patients with advanced colorectal cancer." 07/01/1979 - "Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study." 08/01/1996 - "A home treatment program based on oral ftorafur may be the most desirable option for all patients with advanced colorectal carcinoma." 08/01/1996 - "Advanced colorectal carcinoma: redefining the role of oral ftorafur."
2.	Neoplasms (Cancer) 02/01/1988 - "A marked reduction in the size of a hepatic tumor was observed in this case, and the administration of tegafur has proved effective in prolonging life for over three years." 09/01/1984 - "However, classified by prognostic factors, both the survival and disease free rates were improved in patients with stage III, n (+) ps (+) advanced cancer, to whom Ftorafur alone was administered for a long-term period. " 01/01/1987 - "The agents used for the study were tegafur (T) and UFT, and their effects on inhibiting tumor growth, and on preventing tumors from implanting or recurring were investigated in mice in continuous long-term administrations. " 07/01/1984 - "[Cooperative phase II study of releasing tegafur (SF-SP) against advanced digestive cancers]." 10/20/1979 - "[Experimental study relating to the anti-cancer effect of FT-207 suppository (author's transl)]."
3.	Stomach Neoplasms (Stomach Cancer) 12/01/1994 - "This preliminary report on this ongoing study seems to indicate that long-term postoperative Ftorafur treatment may be beneficial to Stage III gastric cancer patients." 11/01/1990 - "In routine histological preparation of gastric wall and liver specimens, immunohistochemical study of P450 was performed in the total of 116 absolutely noncurative resection of gastric cancer which followed by postoperative administration of tegafur. " 05/01/1985 - "[Phase II study of sustained released granules of tegafur (SF-SP) on inoperable or recurrent gastric cancer]." 01/01/2003 - "An oral tegafur compound, S-1 (TS-1), was developed to potentiate antitumor activity and to reduce gastrointestinal toxicities for patients with gastric cancer. " 12/01/1985 - "In 8 postoperative patients with gastric cancer the effectiveness of fat emulsification of tegafur as a means of improving the drug distribution in the lymphatic tissue was studied. "
4.	Neoplasm Metastasis (Metastasis) 04/01/1986 - "The first and the second study revealed that postoperative bolus injection of MMC and long-term administration of Tegafur improved the survival rate of patients with stage III and lymphatic with serosal metastasis. " 11/01/2013 - "We initiated the internal administration of tegafur-uraci(l UFT 400 mg/day) on postoperative day 44 and continued the treatment for half a year; however, metastasis was frequently noted in the lungs on computed tomography (CT) at 9 months after the operation. " 02/01/2000 - "[A case of complete regression of liver metastases by treatment with Futraful supposition]." 01/01/1994 - "Thirty months after tegafur treatment the patient shows no indications of recurrence or metastasis." 07/01/1989 - "[A multicenter comparative study in patients with liver metastasis to compare tegafur in new forms with existing drugs. "
5.	Breast Neoplasms (Breast Cancer) 10/01/1986 - "SF-SP which contains sustained release granules of tegafur has been reported to be effective for gastrointestinal and breast cancer. " 01/01/1993 - "Oral tegafur in the treatment of metastatic breast cancer: a phase II study." 02/01/1983 - "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study. " 02/01/1995 - "Protracted administration of oral tegafur is active in metastatic breast cancer, with reported response rates ranging from 29 to 44%. " 01/01/1993 - "Between February 1985 and October 1989, 26 patients previously treated for metastatic breast cancer received oral tegafur, at a median daily dose of 1200 mg. Of these, 21 were evaluable for response. "

Related Drugs and Biologics

1.	Uracil
2.	Leucovorin (Folinic Acid)
3.	Fluorouracil (Carac)
4.	Mitomycin (Mitomycin-C)
5.	Cisplatin (Platino)
6.	Tegafur
7.	Cyclophosphamide (Cytoxan)
8.	Doxorubicin (Adriamycin)
9.	irinotecan (Camptosar)
10.	krestin (PSK)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Adjuvant Chemotherapy
3.	Oral Administration
4.	Combination Drug Therapy (Combination Chemotherapy)
5.	Intravenous Injections